Palliative Therapie beim Mammakarzinom

• Literatur

• 1 ECO, European Cancer Observatory. International Agency for Research on Cancer. Im Internet:. http://eu-cancer.iarc.fr Stand: 25.03.2013
• 2 Robert-Koch-Institut und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. Hrsg. Krebs in Deutschland 2007/2008. Häufigkeiten und Trends. 8. Ausgabe. Berlin: RKI; 2012
• 3 Interdisziplinäre S3-Leitlinie für Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Leitlinienprogramm Onkologie der AWMF, Deutschen Krebsgesellschaft e.V. und Deutschen Krebshilfe e.V. Langversion 3.0, Aktualisierung 2012.
• 4 Cardoso F, Costa A, Norton L et al. 1 st International consensus guidelines for advanced breast cancer (ABC1). Breast 2012; 21: 242-252
• 5 Pagani O, Senkus E, Wood W et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?. J Natl Cancer Inst 2010; 102: 456-463
• 6 AGO Kommission Mamma. Aktuelle Empfehlungen zur Diagnostik und Therapie von Patientinnen mit primärem und metastasiertem Brustkrebs. 2013. Im Internet:. http://www.ago-online.de/fileadmin/downloads/leitlinien/mamma/2013_02_Februar/AGO_Mamma_2013/pdf/AGO_Version_2013_D.pdf Stand: 12.03.2013
• 7 Gibson LJ, Dawson CK, Lawrence DH et al. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 2007; (1) CD003370
• 8 Valachis A, Mauri D, Polyzos NP et al. Fulvestrant in the treatment of advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol 2010; 73: 220-227
• 9 Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-529
• 10 Baselga J, Cortés J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119
• 11 Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743
• 12 Metro G, Foglietta J, Russillo M et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 2011; 22: 625-630
• 13 Johnston S, Pippen jr. J, Pivot X et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27: 5538-5546
• 14 Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009; 27: 5529-5537
• 15 OʼShaughnessy J, Miles D, Gray R et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 2010; 28: 7s (suppl abstr 1005)
• 16 Cortes J, OʼShaughnessy J, Loesch D et al. Eribulin monotherapy versus treatment of physicianʼs choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011; 377: 914-923
• 17 Sperduto PW, Chao ST, Sneed PK et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010; 77: 655-661
• 18 Leitlinienprogramm der AWMF und der Deutschen Gesellschaft für Neurologie Hrsg. S2 k-Leitlinie, Hirnmetastasen und Meningeosis neoplastica. Aktueller Stand: 30.09.2011, gültig bis 25.09.2016.
• 19 Kalkanis SN, Kondziolka D, Gaspar LE et al. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96: 33-43
• 20 Kocher M, Soffietti R, Abacioglu U et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011; 29: 134-141
• 21 Linskey ME, Andrews DW, Asher AL et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96: 45-68
• 22 Klein C, Eckl S, Ostgathe C. Schmerztherapie bei der onkologischen Patientin und in der Palliativmedizin. Frauenheilkunde up2date 2013; 2: 103-118
• 23 Van Poznak CH, Temin S, Yee GC. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011; 29: 1221-1227
• 24 Raffaelli L, Scaramuzzo L, Rossi Iommetti P et al. Jaw osteonecrosis related to bisphosphonate treatment of bone metastasis. J Bio Regul Homeost Agents 2010; 24: 115-121
• 25 Leitlinienprogramm der AWMF und der Deutschen Gesellschaft für Mund-, Kiefer- und Gesichtschirurgie (DGMKG) Hrsg. S3-Leitlinie, Bisphosphonat-assoziierte Kiefernekrose (BP-ONJ) und andere medikamentenassoziierte Kiefernekrosen. Aktueller Stand: 15.04.2012, gültig bis 30.04.2015.
• 26 Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28: 5132-5139
• 27 Zagar TM, Higgins KA, Miles EF et al. Durable palliation of breast cancer chest wall recurrence with radiation therapy, hyperthermia, and chemotherapy. Radiother Oncol 2010; 97: 535-540
• 28 van Walsum GA, de Ridder JA, Verhoef C. Resection of liver metastases in patients with breast cancer: survival and prognostic factors. Eur J Surg Oncol 2012; 38: 910-917
• 29 Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev 2004; (1) CD002916